Neuralstem, Inc. (NASDAQ:CUR) was the recipient of a large increase in short interest during the month of December. As of December 15th, there was short interest totalling 1,413,759 shares, an increase of 136.4% from the November 30th total of 598,032 shares. Based on an average daily volume of 6,510,771 shares, the days-to-cover ratio is presently 0.2 days. Currently, 11.3% of the shares of the company are short sold.

A number of large investors have recently modified their holdings of the stock. Vanguard Group Inc. lifted its position in Neuralstem by 1.1% in the 2nd quarter. Vanguard Group Inc. now owns 345,346 shares of the company’s stock valued at $2,000,000 after purchasing an additional 3,853 shares during the last quarter. Blair William & Co. IL lifted its position in Neuralstem by 171.0% in the 2nd quarter. Blair William & Co. IL now owns 87,343 shares of the company’s stock valued at $506,000 after purchasing an additional 55,115 shares during the last quarter. Finally, National Asset Management Inc. lifted its position in Neuralstem by 9.2% in the 2nd quarter. National Asset Management Inc. now owns 22,985 shares of the company’s stock valued at $134,000 after purchasing an additional 1,937 shares during the last quarter. Hedge funds and other institutional investors own 7.05% of the company’s stock.

Shares of Neuralstem (NASDAQ CUR) opened at $1.72 on Friday. The firm has a market cap of $26.05, a PE ratio of -1.04 and a beta of 1.63. Neuralstem has a 52-week low of $0.88 and a 52-week high of $6.60.

WARNING: This report was first posted by Watch List News and is the property of of Watch List News. If you are reading this report on another website, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this report can be viewed at https://www.watchlistnews.com/neuralstem-inc-cur-sees-significant-increase-in-short-interest/1789270.html.

Neuralstem Company Profile

Neuralstem, Inc (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform.

Receive News & Ratings for Neuralstem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem and related companies with MarketBeat.com's FREE daily email newsletter.